{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:36:51Z","timestamp":1790779011598,"version":"4.1.0"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014804","name":"Neurofibromatosis Therapeutic Acceleration Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA166593"],"award-info":[{"award-number":["R01 CA166593"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurofibromatosis type 1 (NF1) is a life-long neurocutaneous disorder characterized by a predisposition to tumor development, including cutaneous neurofibroma (cNF), the hallmark of the disease. cNF is a histologically benign, multicellular tumor formed in virtually most individuals with NF1. It is considered the most burdensome feature of the disorder due to their physical discomfort, cosmetically disfiguring appearance, and psychosocial burden. Management of cNF remains a challenge in the medical field. Effective medicinal treatment for cNF does not exist at this time. Trials aimed at targeting individual components of the neoplasm such as mast cells with Ketotifen have not shown much success. Physical removal or destruction has been the mainstay of therapy. Surgical removal gives excellent cosmetic results, but risk in general anesthesia may require trained specialists. Destructive laser such as CO2 laser is effective in treating hundreds of tumors at one time but has high risk of scarring hypopigmentation or hyperpigmentation that alter cosmetic outcomes. A robust, low-risk surgical technique has been developed, which may be performed in clinic using traditional biopsy tools that may be more accessible to NF1 patients worldwide than contemporary techniques including Er:YAG or Nd:YAG laser. In this review, specific recommendations for management of cNFs are made based on symptoms, clinical expertise, and available resources. Additionally, antiproliferative agents aimed at stimulating cellular quiescence are explored.<\/jats:p>","DOI":"10.1093\/noajnl\/vdz034","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:38:35Z","timestamp":1569890315000},"page":"i107-i116","source":"Crossref","is-referenced-by-count":25,"title":["Management of cutaneous neurofibroma: current therapy and future directions"],"prefix":"10.1093","volume":"2","author":[{"given":"Bahir H","family":"Chamseddin","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-5382","authenticated-orcid":false,"given":"Lu Q","family":"Le","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas"},{"name":"Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, Texas"},{"name":"Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas"},{"name":"Neurofibromatosis Clinic, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"issue":"1","key":"2020062601034462100_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2008.12.051","article-title":"Neurofibromatosis type 1","volume":"61","author":"Boyd","year":"2009","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"2020062601034462100_CIT0002","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J Med Genet."},{"issue":"2","key":"2020062601034462100_CIT0003","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0002-9440(10)63992-2","article-title":"Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells","volume":"158","author":"Muir","year":"2001","journal-title":"Am J Pathol."},{"issue":"3","key":"2020062601034462100_CIT0004","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/jnr.20646","article-title":"Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice","volume":"82","author":"Wu","year":"2005","journal-title":"J Neurosci Res."},{"issue":"2","key":"2020062601034462100_CIT0005","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajpath.2010.10.041","article-title":"The development of cutaneous neurofibromas","volume":"178","author":"Jouhilahti","year":"2011","journal-title":"Am J Pathol."},{"issue":"5","key":"2020062601034462100_CIT0006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J Med Genet."},{"issue":"1","key":"2020062601034462100_CIT0007","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1542\/peds.2007-3204","article-title":"Neurofibromatosis type 1 revisited","volume":"123","author":"Williams","year":"2009","journal-title":"Pediatrics."},{"issue":"2 Suppl 1","key":"2020062601034462100_CIT0008","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1212\/WNL.0000000000005792","article-title":"Cutaneous neurofibromas: current clinical and pathologic issues","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology."},{"issue":"1","key":"2020062601034462100_CIT0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13023-018-0772-z","article-title":"Cutaneous neurofibromas in neurofibromatosis type I: a quantitative natural history study","volume":"13","author":"Cannon","year":"2018","journal-title":"Orphanet J Rare Dis."},{"issue":"5","key":"2020062601034462100_CIT0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/cge.12551","article-title":"Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life","volume":"88","author":"Cohen","year":"2015","journal-title":"Clin Genet."},{"issue":"5","key":"2020062601034462100_CIT0011","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.stem.2009.03.017","article-title":"Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas","volume":"4","author":"Le","year":"2009","journal-title":"Cell Stem Cell."},{"issue":"2 Suppl 1","key":"2020062601034462100_CIT0012","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/WNL.0000000000005788","article-title":"The biology of cutaneous neurofibromas: consensus recommendations for setting research priorities","volume":"91","author":"Brosseau","year":"2018","journal-title":"Neurology."},{"issue":"3","key":"2020062601034462100_CIT0013","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","article-title":"Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2013 and c-kit-dependent bone marrow","volume":"135","author":"Yang","year":"2008","journal-title":"Cell."},{"issue":"7","key":"2020062601034462100_CIT0014","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2044.2004.03757.x","article-title":"Mast cell tryptase: a review of its physiology and clinical significance","volume":"59","author":"Payne","year":"2004","journal-title":"Anaesthesia."},{"issue":"18","key":"2020062601034462100_CIT0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.COT.0000502634.14826.10","article-title":"Defining the research landscape for dermal neurofbromas","volume":"38","author":"Le","year":"2016","journal-title":"Oncology Times."},{"issue":"2","key":"2020062601034462100_CIT0016","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1440-1827.2008.02333.x","article-title":"Actin expression in neural crest cell-derived tumors including schwannomas, malignant peripheral nerve sheath tumors, neurofibromas and melanocytic tumors","volume":"59","author":"Dundr","year":"2009","journal-title":"Pathol Int."},{"key":"2020062601034462100_CIT0017","first-page":"3","article-title":"Translational genetics and genomics: the fundamental nature of NF1 neurofibromas","volume":"1","author":"Riccardi","year":"2007","journal-title":"Transl Genet Genom"},{"key":"2020062601034462100_CIT0018","first-page":"5","article-title":"Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1","author":"Chamseddin","year":"2019","journal-title":"JCI Insight"},{"key":"2020062601034462100_CIT0019","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00000637-198204000-00002","article-title":"Neurofibromatosis\u2014distribution of lesions and surgical treatment","volume":"8","author":"Bromley","year":"1982","journal-title":"Ann Plast Surg"},{"issue":"6","key":"2020062601034462100_CIT0020","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00000637-199106000-00016","article-title":"Use of the carbon dioxide laser in treating multiple cutaneous neurofibromas","volume":"26","author":"Becker","year":"1991","journal-title":"Ann Plast Surg"},{"issue":"3","key":"2020062601034462100_CIT0021","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10103-013-1469-0","article-title":"Comparative study of CO2- and Er:YAG laser ablation of multiple cutaneous neurofibromas in von Recklinghausen\u2019s disease","volume":"29","author":"Kriechbaumer","year":"2014","journal-title":"Lasers Med Sci."},{"issue":"8","key":"2020062601034462100_CIT0022","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bjps.2007.03.035","article-title":"Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I","volume":"61","author":"Levine","year":"2008","journal-title":"J Plast Reconstr Aesthet Surg."},{"issue":"12","key":"2020062601034462100_CIT0023","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41416-018-0073-2","article-title":"Cutaneous neurofibromas in the genomics era: current understanding and open questions","volume":"118","author":"Allaway","year":"2018","journal-title":"Br J Cancer."},{"issue":"2 Suppl 1","key":"2020062601034462100_CIT0024","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1212\/WNL.0000000000005791","article-title":"Considerations for development of therapies for cutaneous neurofibroma","volume":"91","author":"Verma","year":"2018","journal-title":"Neurology."},{"issue":"9","key":"2020062601034462100_CIT0025","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1524-4725.2010.01666.x","article-title":"The megasession technique for excision of multiple neurofibromas","volume":"36","author":"Onesti","year":"2010","journal-title":"Dermatol Surg."},{"issue":"4","key":"2020062601034462100_CIT0026","first-page":"5245","article-title":"Surgical management of giant neurofibroma in soft tissue: a single-center retrospective analysis","volume":"8","author":"Yuan","year":"2015","journal-title":"Int J Clin Exp Med."},{"issue":"2","key":"2020062601034462100_CIT0027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1524-4725.1987.tb00517.x","article-title":"CO2 laser treatment of cutaneous neurofibromas","volume":"13","author":"Roenigk","year":"1987","journal-title":"J Dermatol Surg Oncol."},{"issue":"1","key":"2020062601034462100_CIT0028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s13555-012-0007-5","article-title":"Carbon dioxide laser treatment of cutaneous neurofibromas","volume":"2","author":"Chiang","year":"2012","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"3","key":"2020062601034462100_CIT0029","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000368078","article-title":"Treatment of neurofibromas with a carbon dioxide laser: a retrospective cross-sectional study of 106 patients","volume":"230","author":"M\u00e9ni","year":"2015","journal-title":"Dermatology."},{"issue":"5","key":"2020062601034462100_CIT0030","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1046\/j.1365-2133.2001.04214.x","article-title":"Carbon dioxide laser for removal of multiple cutaneous neurofibromas","volume":"144","author":"Moreno","year":"2001","journal-title":"Br J Dermatol."},{"issue":"3","key":"2020062601034462100_CIT0031","first-page":"296","article-title":"Hypertrophic scars after therapy with CO2 laser for treatment of multiple cutaneous neurofibromas","volume":"28","author":"Ostertag","year":"2002","journal-title":"Dermatol Surg."},{"key":"2020062601034462100_CIT0032","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0738-081X(94)00024-V","article-title":"Carbon dioxide laser for the treatment of cutaneous lesions","volume":"13","author":"Gloster","year":"1995","journal-title":"Clin Dermatol."},{"issue":"3","key":"2020062601034462100_CIT0033","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10103-007-0485-3","article-title":"Non-excision treatment of multiple cutaneous neurofibromas by laser photocoagulation","volume":"23","author":"Elwakil","year":"2008","journal-title":"Lasers Med Sci."},{"issue":"6","key":"2020062601034462100_CIT0034","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1524-4725.2012.02357.x","article-title":"Successful treatment of multiple cutaneous neurofibromas using a combination of shave excision and laser photothermocoagulation with a 1,444-nm neodymium-doped yttrium aluminum garnet laser","volume":"38","author":"Kim","year":"2012","journal-title":"Dermatol Surg."},{"issue":"6","key":"2020062601034462100_CIT0035","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bjps.2016.03.024","article-title":"The use of electrodessication in the treatment of cutaneous neurofibromatosis: a retrospective patient satisfaction outcome assessment","volume":"69","author":"Lutterodt","year":"2016","journal-title":"J Plast Reconstr Aesthet Surg."},{"issue":"2","key":"2020062601034462100_CIT0036","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0007-1226(85)90066-9","article-title":"An operation for the treatment of cutaneous neurofibromatosis","volume":"38","author":"Roberts","year":"1985","journal-title":"Br J Plast Surg."},{"issue":"Suppl 10","key":"2020062601034462100_CIT0037","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1097\/DSS.0000000000000489","article-title":"Undermining and hemostasis","volume":"41","author":"Chen","year":"2015","journal-title":"Dermatol Surg."},{"issue":"3","key":"2020062601034462100_CIT0038","doi-asserted-by":"crossref","first-page":"231","DOI":"10.25122\/jml-2018-0059","article-title":"Facial skin cancer surgery under local anesthesia","volume":"11","author":"Bordianu","year":"2018","journal-title":"J Med Life."},{"issue":"3","key":"2020062601034462100_CIT0039","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0891-8422(23)00709-7","article-title":"Various laser modalities in the treatment of cutaneous lesions","volume":"9","author":"Brauner","year":"1992","journal-title":"Clin Podiatr Med Surg."},{"issue":"12","key":"2020062601034462100_CIT0040","first-page":"36","article-title":"Efficacy of fractional carbon dioxide laser in the treatment of mature burn scars: a clinical, histopathological, and histochemical study","volume":"10","author":"El-Hoshy","year":"2017","journal-title":"J Clin Aesthet Dermatol."},{"issue":"3","key":"2020062601034462100_CIT0041","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol."},{"issue":"3","key":"2020062601034462100_CIT0042","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/14764172.2011.586423","article-title":"Effects of the Nd:YAG 1320-nm laser on skin rejuvenation: clinical and histological correlations","volume":"13","author":"El-Domyati","year":"2011","journal-title":"J Cosmet Laser Ther."},{"issue":"3","key":"2020062601034462100_CIT0043","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/lsm.20607","article-title":"Correlation of histological findings of single session Er:YAG skin fractional resurfacing with various passes and energies and the possible clinical implications","volume":"40","author":"Trelles","year":"2008","journal-title":"Lasers Surg Med."},{"issue":"5","key":"2020062601034462100_CIT0044","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0360-3016(82)90090-6","article-title":"Thermal distribution of magnetic-loop induction hyperthermia in phantoms and animals: effect of the living state and velocity of heating","volume":"8","author":"Storm","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"8","key":"2020062601034462100_CIT0045","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/archderm.1987.01660320053011","article-title":"Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen","volume":"123","author":"Riccardi","year":"1987","journal-title":"Arch Dermatol."},{"key":"2020062601034462100_CIT0046","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archderm.1993.01680260047004","article-title":"A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching","volume":"129","author":"Riccardi","year":"1993","journal-title":"Arch Dermatol"},{"issue":"7","key":"2020062601034462100_CIT0047","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/ajmg.a.37045","article-title":"Ketotifen suppression of NF1 neurofibroma growth over 30 years","volume":"167","author":"Riccardi","year":"2015","journal-title":"Am J Med Genet A."},{"key":"2020062601034462100_CIT0048","article-title":"[NCT00865644] Topical imiquimod 5% cream for treatment of cutaneous neurofibromas in adults with neurofibromatosis 1 no title","author":"Massachusetts General Hospital","year":"2009","journal-title":"Clinicaltrials.gov"},{"key":"2020062601034462100_CIT0049","article-title":"[NCT03090971] Use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in patients with NF1","author":"Funda\u00e7\u00e3o Educacional Serra dos \u00d3rg\u00e3os","year":"2017","journal-title":"Clinicaltrials.gov"},{"key":"2020062601034462100_CIT0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1758-3284-4-30","article-title":"Solitary giant neurofibroma of the neck subjected to photodynamic therapy: case study","volume":"4","author":"Hamdoon","year":"2012","journal-title":"Head Neck Oncol."},{"key":"2020062601034462100_CIT0051","article-title":"[NCT02728388] Photodynamic therapy for benign dermal neurofibromas","author":"Whelan","year":"2016","journal-title":"Clinicaltrials.gov"},{"issue":"12","key":"2020062601034462100_CIT0052","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"1","key":"2020062601034462100_CIT0053","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bjd.13170","article-title":"Use of imatinib in a patient with cutaneous vasculopathy in the context of von Recklinghausen disease\/neurofibromatosis","volume":"172","author":"Khelifa","year":"2015","journal-title":"Br J Dermatol."},{"key":"2020062601034462100_CIT0054","article-title":"[NCT01412892] Use of RAD001 as monotherapy in the treatment of neurofibromatosis 1 related internal plexiform neurofibromas (NFitor)","author":"Assistance Publique - H\u00f4pitaux de Paris","year":"2011","journal-title":"Clinicaltrials.gov"},{"key":"2020062601034462100_CIT0055","article-title":"[NCT02332902] Everolimus for treatment of disfiguring cutaneous lesions in neurofibromatosis1 CRAD001CUS232T (DCLNF1)","author":"The University of Texas Health Science Center - Houston","year":"2014","journal-title":"Clinicaltrials.gov"},{"key":"2020062601034462100_CIT0056","article-title":"[NCT01031901] Topical rapamycin therapy to alleviate cutaneous manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)","author":"The University of Texas Health Science Center - Houston","year":"2009","journal-title":"Clinicaltrials.gov"},{"issue":"26","key":"2020062601034462100_CIT0057","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med."},{"key":"2020062601034462100_CIT0058","article-title":"[NCT02839720] Selumetinib in treating patients with neurofibromatosis type 1 and dermal neurofibroma","author":"National Cancer Institute (NCI)","year":"2016","journal-title":"Clinicaltrials.gov"},{"key":"2020062601034462100_CIT0059","article-title":"[NCT00657202] Ranibizumab for neurofibromas associated with NF1","author":"Massachusetts General Hospital","year":"2008","journal-title":"Clinicaltrials.gov"},{"issue":"2","key":"2020062601034462100_CIT0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pbc.23015","article-title":"Preclincial testing of sorafenib and RAD001 in the Nf(flox\/flox);DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging","volume":"58","author":"Wu","year":"2012","journal-title":"Pediatr Blood Cancer."},{"issue":"3","key":"2020062601034462100_CIT0061","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/pbc.24281","article-title":"Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas","volume":"60","author":"Kim","year":"2013","journal-title":"Pediatr Blood Cancer."},{"key":"2020062601034462100_CIT0062","doi-asserted-by":"crossref","first-page":"7656747","DOI":"10.1155\/2019\/7656747","article-title":"Targeting sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST) in a phase II study of everolimus in combination with bevacizumab (SARC016)","volume":"2019","author":"Widemann","year":"2019","journal-title":"Sarcoma."},{"issue":"4","key":"2020062601034462100_CIT0063","first-page":"752","article-title":"Progesterone receptor expression in neurofibromas","volume":"63","author":"McLaughlin","year":"2003","journal-title":"Cancer Res."},{"key":"2020062601034462100_CIT0064","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2407-5-16","article-title":"Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients","volume":"5","author":"Lammert","year":"2005","journal-title":"BMC Cancer."},{"issue":"2","key":"2020062601034462100_CIT0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.13966","article-title":"Neurofibromatosis type 1: neurofibromas and sex","volume":"174","author":"Sbidian","year":"2016","journal-title":"Br J Dermatol."},{"issue":"16","key":"2020062601034462100_CIT0066","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/hmg\/ddl165","article-title":"Nf1+\/\u2013 mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling","volume":"15","author":"Yang","year":"2006","journal-title":"Hum Mol Genet."},{"issue":"3","key":"2020062601034462100_CIT0067","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1872213X113079990021","article-title":"Imatinib mesylate: an innovation in treatment of autoimmune diseases","volume":"7","author":"Azizi","year":"2013","journal-title":"Recent Pat Inflamm Allergy Drug Discov."},{"issue":"1","key":"2020062601034462100_CIT0068","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D34VW339W4","article-title":"Imiquimod 5 percent cream and the treatment of cutaneous malignancy","volume":"10","author":"Navi","year":"2004","journal-title":"Dermatol Online J."},{"issue":"4","key":"2020062601034462100_CIT0069","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1084\/jem.190.4.451","article-title":"Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts","volume":"190","author":"Zhang","year":"1999","journal-title":"J Exp Med."},{"key":"2020062601034462100_CIT0070","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4236\/ijcm.2015.612128","article-title":"A proof-of-concept assessment of the safety and efficacy of intralesional diclofenac in the treatment of cutaneous neurofibromas","volume":"6","author":"Geller","year":"2015","journal-title":"Int. J. Clin. Med"},{"issue":"5","key":"2020062601034462100_CIT0071","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"2020062601034462100_CIT0072","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer."},{"issue":"24","key":"2020062601034462100_CIT0073","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020062601034462100_CIT0074","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2019.04.027","article-title":"Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219","volume":"133","author":"Melosky","year":"2019","journal-title":"Lung Cancer."},{"issue":"35","key":"2020062601034462100_CIT0075","doi-asserted-by":"crossref","first-page":"57171","DOI":"10.18632\/oncotarget.11036","article-title":"Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors","volume":"7","author":"Ahsan","year":"2016","journal-title":"Oncotarget."},{"issue":"4","key":"2020062601034462100_CIT0076","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1034\/j.1600-0625.2003.00062.x","article-title":"Expression of angiogenic factors in neurofibromas","volume":"12","author":"Kawachi","year":"2003","journal-title":"Exp Dermatol."},{"issue":"12","key":"2020062601034462100_CIT0077","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ajmg.a.32301","article-title":"The role of steroid hormones in the NF1 phenotype: focus on pregnancy","volume":"146A","author":"Roth","year":"2008","journal-title":"Am J Med Genet A."},{"key":"2020062601034462100_CIT0078","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4137\/CPath.S1002","article-title":"Progesterone and estrogen receptors in neurofibromas of patients with NF1","volume":"1","author":"Geller","year":"2008","journal-title":"Clin Med Pathol."},{"issue":"1","key":"2020062601034462100_CIT0079","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1203\/PDR.0b013e31817445b8","article-title":"Schwann cells from human neurofibromas show increased proliferation rates under the influence of progesterone","volume":"64","author":"Overdiek","year":"2008","journal-title":"Pediatr Res."},{"issue":"7","key":"2020062601034462100_CIT0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/mc.20236","article-title":"In vitro studies of steroid hormones in neurofibromatosis 1 tumors and Schwann cells","volume":"46","author":"Fishbein","year":"2007","journal-title":"Mol Carcinog."},{"issue":"1","key":"2020062601034462100_CIT0081","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1590\/S1807-59322008000100008","article-title":"Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1","volume":"63","author":"Cunha","year":"2008","journal-title":"Clinics (Sao Paulo)."},{"issue":"4","key":"2020062601034462100_CIT0082","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000369802","article-title":"Endocrine implications of neurofibromatosis 1 in childhood","volume":"83","author":"Bizzarri","year":"2015","journal-title":"Horm Res Paediatr."},{"issue":"2","key":"2020062601034462100_CIT0083","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0022-3476(98)70245-8","article-title":"Growth hormone replacement and the risk of malignancy in children with neurofibromatosis","volume":"133","author":"Howell","year":"1998","journal-title":"J Pediatr."},{"issue":"1","key":"2020062601034462100_CIT0084","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0022-3476(96)70462-6","article-title":"Precocious puberty, growth hormone deficiency, and neurofibromatosis","volume":"128","author":"Vassilopoulou-Sellin","year":"1996","journal-title":"J Pediatr."},{"issue":"3","key":"2020062601034462100_CIT0085","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.det.2014.03.009","article-title":"Photodynamic therapy","volume":"32","author":"Rkein","year":"2014","journal-title":"Dermatol Clin."},{"issue":"1","key":"2020062601034462100_CIT0086","first-page":"79","article-title":"Photodynamic treatment for viral infections of the skin","volume":"144","author":"Rossi","year":"2009","journal-title":"G Ital Dermatol Venereol."},{"issue":"5","key":"2020062601034462100_CIT0087","doi-asserted-by":"crossref","first-page":"e0178493","DOI":"10.1371\/journal.pone.0178493","article-title":"Doxycycline potentiates antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy in malignant peripheral nerve sheath tumor cells","volume":"12","author":"Lee","year":"2017","journal-title":"Plos One."},{"key":"2020062601034462100_CIT0088","article-title":"[NCT01682811] Photodynamic therapy (PDT) for benign dermal neurofibromas (NF1)","author":"Whelan","year":"2012","journal-title":"Clinicaltrials.gov"},{"issue":"3","key":"2020062601034462100_CIT0089","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-013-1195-2","article-title":"Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature","volume":"114","author":"Vranceanu","year":"2013","journal-title":"J Neurooncol."},{"issue":"8","key":"2020062601034462100_CIT0090","doi-asserted-by":"crossref","first-page":"e1007274","DOI":"10.1371\/journal.pcbi.1007274","article-title":"A benchmark of computational CRISPR-Cas9 guide design methods","volume":"15","author":"Bradford","year":"2019","journal-title":"PLoS Comput Biol."},{"key":"2020062601034462100_CIT0091","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7371-2_1","article-title":"Molecular regulation of cellular quiescence: a perspective from adult stem cells and its niches","volume":"1686","author":"So","year":"2018","journal-title":"Methods Mol Biol."},{"key":"2020062601034462100_CIT0092","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-7371-2_2","article-title":"An in vitro model of cellular quiescence in primary human dermal fibroblasts","volume":"1686","author":"Mitra","year":"2018","journal-title":"Methods Mol Biol."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdz034\/30075851\/vdz034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/2\/Supplement_1\/i107\/33429892\/vdz034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/noa\/article-pdf\/2\/Supplement_1\/i107\/33429892\/vdz034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T07:59:44Z","timestamp":1721807984000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/2\/Supplement_1\/i107\/5576129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":92,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2020,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdz034","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2019,12,16]]}}}